Bare Financial Services
ZBIO icon

Bare Financial Services’s Zenas BioPharma ZBIO Stock Holding History

Bare Financial Services’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.56K Hold
95
– – ﹤0.01% 1132
2026
Q2 		$2.41K Buy
95
+81
+579% +$1.61K ﹤0.01% 1090
2026
Q1 		$274 Buy
+14
New +$314 ﹤0.01% 1713

Other funds holding ZBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Bare Financial Services's ZBIO Position: Q3 2026 in Review

Bare Financial Services held its Zenas BioPharma (ZBIO) position steady in Q3 2026 at 95 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

Bare Financial Services first reported a position in ZBIO in Q1 2026 and has held it in 3 quarters since. 48 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

  • Bare Financial Services held 95 shares of Zenas BioPharma worth $2.56K as of Q3 2026.
  • Bare Financial Services left its Zenas BioPharma share count unchanged in Q3 2026.
  • Zenas BioPharma made up ﹤0.01% of Bare Financial Services's portfolio in Q3 2026, its #1132 holding.
  • Bare Financial Services first reported a position in Zenas BioPharma in Q1 2026 and has held it in 3 quarters since.
  • 48 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.